alexa Capecitabine And Sorafenib: Incidence Of Hand-foot Syndrome, Adherence To Treatment And Quality Of Life In Patients During Chemotherapy
ISSN: 2167-0870

Journal of Clinical Trials
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

6th World Pharmacists and Clinical Pharmacy Annual Congress
May 22-23, 2017 Chicago, USA

Lais S Amaral, Graziele B Ferrari, Marilia B Visacri, Joao P O Guarnieri and Patricia Moriel
University of Campinas, Brazil
Posters & Accepted Abstracts: J Clin Trials
DOI: 10.4172/2167-0870-C1-014
Abstract
Statement of the Problem: Capecitabine (CAP) and Sorafenib (SOR) are oral antineoplastics indicated for colorectal (CR) and gastric (ST) cancer and hepatocellular carcinoma (HCC), respectively. If not taken properly, the treatment may be at risk. The pharmacist develops an important role to guarantee the adherence to oral antineoplastics ensuring the right information which directly influences in treatment. The purpose of this study is to describe the patients in use of CAP and SOR, the incidence of hand-foot syndrome (HSF), adherence to therapy and quality of life (QoL). Methodology & Theoretical Orientation: This is a prospective, longitudinal and observational study. The patients were followed up during three cycles of chemotherapy and analyzed for HFS incidence based on self-observation; knowledge to therapy with MedTake test; adherence to treatment with Morisky-Green test. QoL was analyzed before the first and after the third cycle of chemotherapy through the general EORTC-QLC-30 and specific questionnaires EORTC-QLC-ST-022 for ST, EORTC-QLC-CR-29 for CR for patients in treatment with CAP and, before and after the first cycle of chemotherapy through the general EORTC-QLC-30 and specific questionnaire EORTC-QLC-HCC-18 for patients in treatment with SOR for HCC. Findings: The patients were male (CAP 53.85%; SOR 93.33%) Caucasian (CAP 76.92%; SOR 86.67%) and tumors were in advanced stages (CAP 53.85% stage IV; SOR 60.00% BCLC C). MedTake indicated a high knowledge to therapy and, in both cases; medicine dosage was the most common mistake. Morisky-Green also indicated a high adherence to both therapies but patients frequently forgot to take their medicines and were careless about the timetable. The QoL decreased in both cases and the HFS was common in patients taking CAP at the second and third cycles of chemotherapy. Conclusion & Significance: QoL decreased despite the fact that the adherence to therapies was high.
Biography

Lais S Amaral has completed her Bachelor’s degree in Pharmacy from University of Campinas, Brazil and is currently a Master's student at Pharmacology at School of Medical Sciences, University of Campinas, Brazil. Her research interests include pharmaceutical care in oncology, adverse drug reactions and biomarkers for adverse events.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords